Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria

BackgroundLenalidomide has demonstrated remarkable efficacy for therapy of lower-risk myelodysplastic syndromes (MDS) associated with 5q−. The present evaluation aimed to describe the characteristics and outcomes of low-risk MDS patients treated with lenalidomide in Austria.Patients and MethodsFor this retrospective, multicenter, observational analysis of MDS patients who received lenalidomide, data were collected at various hospitals in Austria over a period of 3 years. MDS classification, previous and current MDS therapies, and outcome and safety of lenalidomide were evaluated.ResultsForty-six percent of the patients (n = 23) had a 5q− syndrome, while 12% (n = 6) exhibited 5q− plus additional aberrations or isolated 5q− but ≥ 5% blasts in the bone marrow (10%, n = 5). The remaining 32% of patients (n = 16) had MDS with other World Health Organization classifications. Seventy percent belonged to lower International Prognostic Scoring System risk classes. Sixteen centers participated, involving a total of 50 patients. Most frequently used lenalidomide doses were 10 mg and 5 mg on days 1 to 21 of a 28-day cycle. Seventy-five percent of the patients received 11 months of treatment, with a median therapy period of 3.5 months; median follow-up was 3.9 months (range, 0-26 months). Response rate, defined as transfusion independence during the 2 months after lenalidomide therapy, was 64%. Median overall survival was not reached.ConclusionLenalidomide was well tolerated and is an effective and well-tolerated option for therapy of patients with 5q− syndrome but also lower-risk MDS patients with other World Health Organization classifications in clinical practice.